Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ixazomib plus dexamethasone versus physician's choice in relapsed or refractory systemic light chain amyloidosis
MOH_2017-05-07_000374Phase 3Recruiting
- Sponsor
- Millennium Pharmaceuticals
- Start
- Oct 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ixazomib and dexamethasone in light-chain amyloidosis (2 arms), sponsored by Millennium Pharmaceuticals. Started Oct 2012; status: recruiting.
02
Drugs
ixazomibdexamethasone
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on MOH_2017-05-07_000374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-07_000374.